Non-industry-sponsored clinical trials landscape: 2019

When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase from 32.1% to 34.5% in 2019. Credit: avarand on Shutterstock.

A clinical trial can be sponsored by an industry (company) or non-industry (government, individual/investigator-initiated, or institution).

Free Whitepaper

Disruptive start-ups to watch out for

2021 was a record-breaking year, with more businesses breaking into the billion-dollar club. Many start-ups have achieved or retained the unicorn status by the end of the year to reflect nearly a fivefold growth from that in 2020. This boom can be linked to a financing frenzy spurred by the quick adoption of technology and innovative solutions by start-ups gaining traction in response to the pandemic. However, the start-up ecosystem is now facing turbulent times for fundraising as investors seek long-term business strategies, valuations, and a route to profitability amid uncertain market circumstances. Nevertheless, 2022 has the potential to carry forward the momentum with multiple entities having a fair chance of being in the right place when aided by the right technologies. GlobalData leverages the power of alternative data to examine the health of start-ups across multiple dimensions including the quality of their innovations, market presence, and the funding they can attract. This helps our clients to analyze the disruptive potential of start-ups for early alliances, investments, and acquisition prospects to develop future-proof strategic roadmaps for a competitive advantage. Read our report and gather insights on the following topics:

Recent Unicorn trends
Unicorns in 2022
Future Unicorns
Start-ups to watch out for

Start-up ecosystem outlook by top geographies

by GlobalData

Enter your details here to receive your free Whitepaper.

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Figure one: Non-industry-sponsored clinical trials by year. Credit: GlobalData.

When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase, from 32.1% of all clinical trials that year to 34.5% in 2019. This can be seen in figure one.

An analysis can be completed for those non-industry-sponsored clinical trials in 2019 by using the clinical trials database of GlobalData’s Pharma Intelligence Centre. In this article, a small number of phase zero, phase one / two, phase two / three and phase three / four trials were combined with phase one, phase two, phase three and phase four trials, respectively.

Figure two: 2019 non-industry-sponsored clinical trials by phase. Credit: GlobalData.

When looking at non-industry-sponsored clinical trials in 2019 in the database, it can be seen that phase two clinical trials outnumbered all other phases. Phase two clinical trials made up 49.7% of all clinical trials in 2019, with phase four following with 19.4%, phase one next with 16.4% and phase three with 14.5%. This can be seen in figure two.

Figure three: 2019 non-industry-sponsored clinical trials by therapy area. Credit: GlobalData.

Lastly, oncology was the top therapy area for non-industry sponsored clinical trials in 2019, as can be seen in figure three. They made up 25.7% of all clinical trials. The central nervous system (CNS) was second with 23.5%, followed by cardiovascular (8.9%), infectious disease (8.5%) and metabolic disorders (7.4%). Oncology, CNS, cardiovascular and infectious disease clinical trials all showed an increase in 2019 from 2018.